Bristol-Myers Squibb Company
42.60-0.22 (-0.51%)
Oct 29, 4:00:02 PM EDT · NYSE · BMY · USD
Key Stats
Market Cap
86.71BP/E (TTM)
17.11Basic EPS (TTM)
2.49Dividend Yield
0.06%Recent Filings
10-Q
Q2 FY2025 results
Bristol Myers Squibb's Q2 revenues edged up 1% y/y to $12.3B, with the Growth Portfolio surging 18% y/y on strong demand for Opdivo (up 7%), Reblozyl (up 34%), and Breyanzi (up 125%), while Legacy Portfolio dipped 14% y/y amid generic erosion on Revlimid and others; q/q, revenues rose 4% from Q1's $11.2B. Gross margin held steady at 72.5%, but operating income fell 38% y/y to $943M due to a $1.5B Acquired IPRD charge from the BioNTech deal, driving diluted EPS down 23% y/y to $0.64—consistent with 2.038B shares. Cash swelled to $12.6B, with operating cash flow at $5.9B YTD and free cash flow of $5.3B after $621M capex, while long-term debt eased to $44.5B with $5B revolver availability. The May 2seventy bio acquisition for $287M cash bolstered Abecma rights, recognizing marketed product assets. Yet patent challenges on Eliquis in Europe risk early generic entry.
8-K
BMS Q2 revenues rise 1%
Bristol Myers Squibb reported Q2 2025 revenues of $12.3 billion, up 1% year-over-year, driven by 18% growth in its $6.6 billion Growth Portfolio amid legacy declines. A $1.5 billion Acquired IPRD charge from the BioNTech partnership hammered GAAP EPS to $0.64, yet non-GAAP EPS held at $1.46. The company raised full-year revenue guidance to $46.5-47.5 billion and non-GAAP EPS to $6.35-6.65, signaling pipeline momentum. Growth outpaces erosion.
8-K
BMS appoints new CMO
Bristol Myers Squibb announced on July 25, 2025, that Dr. Samit Hirawat will step down as Executive Vice President, Chief Medical Officer, and Head of Development effective August 1, 2025, transitioning to an advisory role until his departure on November 1, 2025. The company appointed Dr. Cristian Massacesi, former Chief Medical Officer at AstraZeneca and Alexion, to the role starting August 1, bringing over 20 years of biopharma experience in advancing clinical studies and securing regulatory approvals across oncology and other areas. This leadership shift ensures continuity in pipeline development amid recent product approvals in key therapeutic fields. Hirawat's exit highlights a smooth handover.
8-K
Annual meeting results affirm leadership
Bristol-Myers Squibb shareholders at the May 6, 2025 annual meeting elected all 11 director nominees, with votes ranging from 1.43 billion to 1.53 billion for amid 241 million broker non-votes. They approved executive compensation advisory vote by 1.44 billion for and ratified Deloitte & Touche as 2025 auditors with 1.72 billion yeses. Shareholder proposals on financial sustainability and halting DEI efforts failed decisively, signaling strong board and management support. No changes to governance emerged.
10-Q
Q1 FY2025 results
Bristol Myers Squibb's Q1 FY2025 revenues fell 6% y/y to $11.2B, with growth products up 16% to $5.6B on strong demand for Opdivo (up 9%), Reblozyl (up 35%), and Breyanzi (up 146%), while legacy brands dropped 20% to $5.6B amid Revlimid's 44% generic erosion and Eliquis' 4% dip from Medicare Part D redesign. Gross margin held at 73%, but operating income swung to $2.1B from a $11.5B loss, thanks to absent $12.9B IPRD charges; diluted EPS rose to $1.20 from -$5.89, reconciling with 2.04B shares. Cash from operations hit $2.0B, lifting cash to $10.9B against $49.5B debt, with $5B revolver available. Recent deals include a $100M BioArctic license for Alzheimer's assets and a pending $286M 2seventy bio buy for Abecma rights. Yet generic competition erodes key revenues faster than expected.
IPO
Website
Employees
Sector
Industry
ABBV
AbbVie Inc.
225.14-2.40
AMGN
Amgen Inc.
291.77-0.32
AZN
Astrazeneca PLC
82.23-0.38
BIIB
Biogen Inc.
147.86-1.27
JNJ
Johnson & Johnson
186.60-0.33
LLY
Eli Lilly and Company
813.53-6.57
NVS
Novartis AG
121.80-1.63
PFE
Pfizer, Inc.
24.29-0.21
TAK
Takeda Pharmaceutical Company L
13.77-0.33
TEVA
Teva Pharmaceutical Industries
20.23+0.45